Credit to another poster elsewhere. Mention in same note as PFE:
Global Roundup: Two Big Deals Highlighting Biopharma Growth in China and More Published: Nov 19, 2020 By Alex Keown
In addition to the Pfizer and LianBio focus on China, Florida-based Generex Biotechnology closed a $50 million licensing and development agreement with a consortium of partners in China for the Ii-Key vaccine platform technology from Generex subsidiary NuGenerex Immuno-Oncology. The fee provides for the exclusive use of the Ii-Key vaccine platform for infectious disease and cancer in China and its territories. The agreement includes the first Ii-Key platform project for the development and commercialization of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China, with a $5 million upfront licensing fee, 100% funding for manufacturing, development and commercial registration, a $20 million success fee for approval Ii-Key- SARS-CoV-2 vaccine in China, and royalty payments for COVID vaccine sales in China with the potential to reach several billion dollars, the company said.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.